{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:40:27Z","timestamp":1781286027185,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jdiacomp.2023.108650","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T13:10:26Z","timestamp":1700745026000},"page":"108650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor"],"prefix":"10.1016","volume":"38","author":[{"given":"Sho","family":"Wakamatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Jojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Niitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshie","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tomaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108650_bb0005","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apt.14327","article-title":"Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011\u20132014 National Health and nutrition examination survey","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with Type2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0020","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0025","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.3390\/ijms20205237","article-title":"The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma","volume":"20","author":"Jojima","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0030","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cmi.2016.62","article-title":"Interleukin-33 in the pathogenesis of liver fibrosis: alarming ILC2 and hepatic stellate cells","volume":"14","author":"Ralf","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: the new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2332\/allergolint.10-RAI-0186","article-title":"IL-33 and IL-33 receptors in host defense and diseases","volume":"59","author":"Oboki","year":"2010","journal-title":"Allergol Int"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s12967-020-02661-w","article-title":"Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment","volume":"18","author":"Wang","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0055","doi-asserted-by":"crossref","first-page":"33649","DOI":"10.18632\/oncotarget.9259","article-title":"IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0060","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/eji.201444969","article-title":"IL-33 activates eosinophils of visceral adipose tissue both directly and via innate lymphoid cells","volume":"45","author":"Hashiguchi","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"Fujii","year":"2013","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0070","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/jm901893x","article-title":"(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment","volume":"53","author":"Kakinuma","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0075","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0080","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165369","article-title":"Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis","volume":"8","author":"Kang","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.22952","article-title":"CCR2 promotes hepatic fibrosis in mice","volume":"50","author":"Seki","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0095","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fimmu.2020.00354","article-title":"Systemic MCP-1 levels derive mainly from injured liver and are associated with complications in cirrhosis","volume":"11","author":"Queck","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/cmi.2016.63","article-title":"Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells","volume":"15","author":"Tan","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep4.1026","article-title":"Identification of a novel alpha-fetoprotein-expressing cell population induced by the Jagged1\/Notch2 signal in murine fibrotic liver","volume":"1","author":"Nakano","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jdiacomp.2023.108650_bb0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor),alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndr"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723002489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723002489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:17:15Z","timestamp":1761005835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723002489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1056872723002489"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108650","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108650"}}